Immunotherapy for Diffuse Large B-Cell Lymphoma: A Narrative Review

A narrative review document discussing immunotherapy treatments for Diffuse Large B-Cell Lymphoma (DLBCL). The 24.6 KB document, authored by Anna Aureli and last updated in May 2026, provides an overview of current treatments, including monoclonal antibodies, CAR-T cell therapy, and their clinical outcomes. It notes that standard frontline therapy is successful in about 60% of cases, while 30-40% of patients experience relapse or refractory disease.

Use Cases

• Literature review on DLBCL immunotherapy based on the described overview of treatments and mechanisms.
• Comparative analysis of treatment efficacy based on the mentioned clinical outcome statistics.
• Identifying research gaps in advanced immunotherapies based on the review of bi-/trispecific antibodies and CAR-T cells.

Strengths

• Provides specific efficacy statistics, noting standard therapy success in about 60% of DLBCL cases.
• Covers a range of advanced immunotherapies as described, including CAR-T cells and antibody-drug conjugates.
• Document is under a permissive CC-BY-4.0 license for reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 24.6 KB size suggests a limited-scope document rather than a large data corpus.

Provenance

Source

figshare, author Anna Aureli.

Collection Method

Likely a literature review and synthesis by the author.

Freshness

Last updated 2026-05-28 05:30:09; freshness should be verified.